Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Cardiovascular

Aspruzyo Sprinkle (ranolazine) extended release granules

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

Medication Name

Approval Date

Category

Description

Aspruzyo Sprinkle (ranolazine) extended release granules

Feb 2022

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle